abstract |
The present invention relates to the obtention of a genetically modified bacterial lineage (strain) engineered to produce and secrete LPS-free Hsp65 protein. Moreover, the present invention also describes the use of this strain and pharmaceutical compositions containing same for preventing and treating inflammatory and autoimmune diseases. |